On October 29, 2019 Danaher Corporation (NYSE: DHR) ("Danaher") reported that its wholly owned subsidiary, DH Europe Finance II S.à r.l. ("Danaher International II"), has priced an offering of (Press release, Danaher, OCT 29, 2019, View Source [SID1234549995]):
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
$700,000,000 principal amount of 2.050% senior notes due 2022 at an offering price of 99.994% of the principal amount;
$700,000,000 principal amount of 2.200% senior notes due 2024 at an offering price of 99.952% of the principal amount;
$800,000,000 principal amount of 2.600% senior notes due 2029 at an offering price of 99.903% of the principal amount;
$900,000,000 principal amount of 3.250% senior notes due 2039 at an offering price of 99.809% of the principal amount; and
$900,000,000 principal amount of 3.400% senior notes due 2049 at an offering price of 99.756% of the principal amount (collectively, the "senior notes").
Danaher estimates that the net proceeds from the sale of the senior notes in this offering will be approximately $3.97 billion, after deducting the underwriting discounts and estimated offering expenses payable by Danaher. Danaher anticipates using the net proceeds to fund a portion of the cash consideration payable for, and certain costs associated with, its acquisition of the Biopharma Business of GE Life Sciences (the "GE Biopharma Acquisition"). Pending completion of the GE Biopharma Acquisition, Danaher may invest the net proceeds of the offering in short-term bank deposits or invest them in interest-bearing, investment-grade securities. The senior notes will be fully and unconditionally guaranteed on a senior unsecured basis by Danaher. The offering is expected to close on November 7, 2019, subject to customary closing conditions.
The offering is being made pursuant to an effective shelf registration statement on file with the U.S. Securities and Exchange Commission.
The offering of senior notes may be made only by means of a prospectus and prospectus supplement. A copy of the prospectus and prospectus supplement relating to the securities can be obtained by calling BofA Securities, Inc., toll-free at 1-800-294-1322, Mizuho Securities USA LLC, toll-free at 1-866-271-7403, MUFG Securities Americas Inc., toll-free at 1-877-649-6848, U.S. Bancorp Investments, Inc., toll-free at 1-877-558-2607, or Wells Fargo Securities, LLC, toll-free at 1-800-645-3751.
This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, the senior notes or any other securities, nor shall there be any offer, solicitation or sale of any security mentioned in this press release in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.